Takeda-ism: Shaping the Future of Global Pharmaceuticals — Transformation and Value Creation through Philosophy-Led Management at Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (Takeda) is a leading Japanese pharmaceutical company with a history spanning over 240 years since its founding in 1781¹. However, it is by no means a traditional, old-fashioned firm. In recent years, through bold transformations—most notably the acquisition of the Irish pharmaceutical giant Shire (announced in 2018 and completed in 2019)—it has evolved significantly into a leading global R&D-driven biopharmaceutical company².

During this remarkable period of transition, Takeda’s corporate philosophy—particularly its core, "Takedaheadism"—has served as more than just a historical slogan. It is actively utilized as a "compass" to guide complex global management.

This article focuses on Takeda’s corporate philosophy system: its Purpose (reason for being), Vision (the future it aims for), Values (Takedaheadism), and specific Promises (Patient, People, Planet, Data & Digital), as well as the prioritized action guidelines known as "PTRB" (Patient, Trust, Reputation, Business) that translate these ideals into daily actions. We will delve into how these philosophies specifically influence Takeda’s management strategy, organizational culture, brand identity, and the creation of sustainable corporate value.

For executives, professionals in organizational culture and branding, and students considering their future careers, Takeda’s case provides numerous practical insights into how philosophy can be leveraged in management.

At the heart of Takeda’s management strategy and daily operations lies its corporate philosophy system. These are not merely decorative words; they cover everything from the company’s reason for existence to specific behavioral principles, serving as the foundation that indicates the direction for the entire organization.

The Core of the Philosophy System

Takeda’s corporate philosophy answers the questions: "Who are we, what do we achieve, how do we do it, and why does it matter?" It is structured to leverage a long history and tradition within modern activities³. The system consists of several interrelated elements:

• Purpose: "Better Health for People, Brighter Future for the World." This represents Takeda’s fundamental "Why"—the reason it exists in society³.
• Vision: "For all patients, for our people, for the planet. With this promise, we will continue to create innovative medicines." This clarifies Takeda’s long-term goal, or "What" it aims to achieve³.
• Values (Takedaheadism): At the core is Integrity, supported by Fairness, Honesty, and Perseverance. This defines the fundamental "How"—the stance Takeda takes in its business activities³.
• Promises: These are specific commitments to realize the Vision. They consist of vows to key stakeholders—Patient, People, and Planet—along with Data & Digital as the foundation supporting them³.

These elements are summarized in the table below.

Table 1: Overview of Takeda Pharmaceutical Company’s Corporate Philosophy System

This system demonstrates Takeda’s long-term business perspective and its deep awareness of its role in society.

PTRB: A Practical Tool for Guiding Decisions

In translating Takedaheadism into specific actions, the "PTRB" action guidelines play a crucial role. These guidelines follow a strict order of priority: 1. Patient, 2. Trust, 3. Reputation, and 4. Business³. This hierarchical structure is extremely significant; "Business" is positioned as something that should be realized solely as a result of prioritizing the Patient, Trust, and Reputation.

The PTRB framework is designed to function as a practical decision-making criterion in daily operations and strategic discussions. For instance, when considering a new business venture, Takeda’s "way" involves discussing how that venture contributes to PTRB and making decisions based on this standard⁴. The CEO himself emphasizes the patient, society (trust and reputation), and the company's reputation as top priorities⁵.

Following the Shire acquisition, Takeda transformed into a highly diverse global organization, with approximately 90% of its employees now being non-Japanese⁶⁷. In such a large and complex organization, maintaining consistent values and decision-making axes among employees with different cultures and backgrounds is a major management challenge. The PTRB model, being simple, memorable, and clearly prioritized, is thought to play a vital role in addressing this challenge.

The clear starting point of "Patient First" serves as an non-negotiable principle when facing ethically or strategically difficult trade-offs. Placing "Business" last distinguishes the company from short-term profit-seeking and reinforces a long-term stakeholder-centric perspective rooted in its Purpose. This, in turn, can lead to enhanced Trust and Reputation.

Thus, the PTRB model is more than a statement of values; it is an intentionally designed "operational tool" for embedding core philosophy into specific decision-making mechanisms. It functions as a mechanism to provide a cultural anchor and align the direction of the entire organization amidst the complexities of global scale and post-merger integration. It represents an attempt to transform the abstract value of "Integrity" into a chain of practical, prioritized actions.

Unwavering Values Cultivated by History

Takeda’s philosophy system, particularly Takedaheadism, did not emerge overnight. It has been cultivated and evolved over a long history of more than 240 years.

At the time of the company’s founding, the first Chobei Omiya based his business on the principle that "Business is people, and moreover, the harmony of people," rooted in the concept of "Harmony is to be valued" from Prince Shotoku's Seventeen-Article Constitution¹. This spirit was first documented as the "Nori" (Principles) in 1940 by the fifth-generation president, Chobei Takeda. It established items such as "Serving the public and reporting to the country," "Working together in harmony," "Striving for diligent study," "Valuing frugality and avoiding vanity," and "Observing etiquette and maintaining humility"¹. Through this, values such as social contribution, cooperation, self-improvement, integrity, and courtesy were established as the company’s fundamental philosophy alongside the original spirit of "Harmony."

Takeda’s philosophy continued to evolve with the times. In 2002, then-President Kunio Takeda presented modern principles such as "Reverence for the dignity of life and a high sense of ethics"¹. This eventually evolved into the current system of "Takedaheadism," centered on Integrity and composed of Fairness, Honesty, and Perseverance, with the addition of the specific PTRB action guidelines¹. The introduction of PTRB, in particular, can be seen as a way to share and instill values in a form easily understood by employees from diverse cultural backgrounds as the company globalized¹.

While Takeda cherishes its long history¹, it also emphasizes its recent bold transformations, exemplified by the Shire acquisition, and its identity as a global corporation². The evolution of the philosophy reflects these two aspects: "Tradition" and "Innovation." Companies often struggle between long-standing traditions and the demands of global change or M&A-driven transformation. Takeda actively positions Takedaheadism as something rooted in history but adapted for the present and future¹.

The evolution from "Harmony" to "Nori" and then to the modern "Takedaheadism/PTRB" demonstrates Takeda's ability to reinterpret and adapt its core values for modern relevance and global communication. This allows Takeda to use history as a source of legitimacy and internal cohesion (for example, there are accounts of Takedaheadism being rooted even within the families of employees⁸) while utilizing the adapted philosophy (PTRB) as a future-oriented strategic tool⁴.

Takeda strategically positions its philosophy not as a static legacy, but as an "adaptable framework." This ensures that while drawing strength and stability from 240 years of history, the philosophy remains effective and practical for addressing modern challenges such as globalization and digital transformation. It is a conscious effort to bridge the past and the future.

Philosophy Drives Takeda’s Global Strategy

Takeda’s corporate philosophy is more than just a company motto or code of conduct; it is a driving force that powerfully supports the formulation and execution of specific strategies to win in the global market. From business portfolio transformation through M&A to the acceleration of innovation and the establishment of global governance, the philosophy serves as a vital guide.

Impact on M&A and Business Portfolio Transformation

The most iconic move in Takeda’s recent strategy was the massive acquisition of Shire. The objectives of this acquisition were multifaceted: mutual complementarity in gastroenterology and neuroscience, achieving a leading position in rare diseases and plasma-derived therapies, complementing strengths in oncology and vaccines, and strengthening the R&D pipeline while expanding the global business foundation⁹.

This bold decision is closely linked to Takeda’s Purpose of contributing to "Better Health for People, Brighter Future for the World" and its Vision of "continuing to create innovative medicines." In particular, the focus on rare diseases, where treatment satisfaction is low (high unmet medical needs), can be interpreted as a concrete manifestation of the philosophy of "Putting the Patient at the center."

On the other hand, this massive acquisition, valued at approximately ¥7 trillion, raised external concerns regarding increased financial risk and the difficulties of the integration process¹⁰. In fact, following the acquisition, Takeda prioritized the reduction of interest-bearing debt and proceeded with the sale of non-core businesses, such as its consumer healthcare business and parts of its diabetes treatment business⁴.

Takeda’s corporate philosophy, particularly the PTRB priorities, likely influenced these decisions. Beyond pure financial rationality, the perspective of prioritizing "Patient," "Trust," and "Reputation" became part of the criteria for determining which businesses to focus on and which to divest. Management has positioned these divestitures as a demonstration of Takeda’s resolve to "invest capital intensively and develop based on this Purpose"⁴.

Large-scale M&A inherently involves significant financial risks (increased debt¹¹) and complex integration processes. Takeda publicly justified this acquisition from a strategic standpoint⁹, explaining it in a way consistent with its philosophy (delivering innovative medicines to patients – Patient/Vision). Using philosophy (Purpose/Vision) as a basis for justification demonstrates that the action aligns with a long-term corporate identity rather than short-term opportunism, which helps in gaining internal and external support.

However, the PTRB hierarchy (Patient/Trust/Reputation > Business) can theoretically function as a "constraint" as well. It encourages incorporating considerations beyond pure financial profit—such as the impact on patients and trust from society—into the decision-making process. This may lead to integration processes or divestment decisions that differ from those a purely finance-driven acquirer might make. This may explain the sale of certain businesses to concentrate resources on core areas aligned with the Purpose⁴.

External criticism¹¹ highlights the tension between a philosophy-driven strategy and the financial prudence or risk perceived by the market. In large-scale portfolio shifts like the Shire acquisition, Takeda appears to use its philosophy system both as a basis for "strategic justification" (showing alignment with long-term Purpose) and as a "guiding framework" for subsequent integration and divestment decisions (prioritizing areas of focus through PTRB). This shows a complex interaction where philosophy justifies bold actions while potentially imposing constraints or priorities different from pure financial optimization, triggering external debate¹¹.

Accelerating Innovation and Digital Transformation

Takeda’s Vision to "continue to create innovative medicines" and its Purpose to contribute to "Better Health for People, Brighter Future for the World" are at the very heart of its R&D activities. The company concentrates its R&D resources on key areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines¹², investing approximately ¥450 billion annually in R&D¹³. Furthermore, through an aggressive partnership strategy that accounts for more than 60% of its pipeline, Takeda incorporates innovative external ideas and technologies to accelerate innovation¹³.

Of particular note here is that "Data & Digital" is explicitly positioned as one of the "Promises" in the corporate philosophy³. This is based on the necessity of accelerating digital transformation (DX) following the Shire acquisition² and the philosophy of "creating innovation through the power of data and digital." Based on this promise, Takeda is actively promoting investment in digital technology and the recruitment and training of specialized talent (including plans to hire hundreds of new employees and upskill existing ones)². Through the use of data-driven insights and operational efficiency, the ultimate goal is to "deliver more innovative medicines to patients faster"¹⁴; digitalization is recognized as an indispensable means to that end.

The traditional pharmaceutical business model faces challenges in R&D productivity and the speed of bringing new drugs to market. Data analysis and digital technology offer potential solutions by accelerating research, improving clinical trials, increasing manufacturing efficiency, and enabling more effective communication with patients and healthcare professionals. Realizing Takeda’s core Purpose (Health/Future) and Vision (Innovative Medicines) depends on overcoming these industry challenges.

By elevating "Data & Digital" to a core "Promise," Takeda suggests that DX is not merely an operational improvement but a "fundamental strategic enabler" necessary to fulfill its philosophy-based commitments—particularly to the Patient (faster delivery), Business (efficiency-driven development), and People (talent development through new ways of working). The aggressive acquisition¹⁵ and internal development¹⁴ of digital talent underscore this strategic commitment.

Takeda’s integration of "Data & Digital" into its core philosophy is an expression of the recognition that mastering digital capabilities is "indispensable" for realizing its long-standing Purpose and Vision in the modern era. It redefines DX from a mere technical project into a strategic necessity deeply linked to the company’s identity and core mission of contributing to patients.

Establishing a Global Governance Structure

Takeda clearly positions a robust corporate governance structure as essential for realizing its Purpose and Vision based on Takedaheadism⁷. Building a rapid decision-making system that ensures soundness and transparency is considered the foundation of values-based management.

One concrete manifestation of this is the composition of the Board of Directors. The Board consists of experienced global leaders, the majority of whom (e.g., 12 out of 16) are independent external directors⁷. Each director possesses not only leadership experience in global corporations but also diverse backgrounds, including knowledge of global governance standards and expertise in law and finance⁷. This aims to ensure oversight from multiple perspectives and alignment with global standards and the corporate philosophy.

Furthermore, Takeda complies with and implements all principles of Japan’s Corporate Governance Code¹⁶, viewing this as a natural response rooted in its own values⁷. Through executive management bodies such as the Business Support Committee (BSC) and the Risk, Ethics & Compliance Committee (RECC)¹⁷, as well as the Takeda Global Code of Conduct—which sets out principles for all employees to follow¹⁸—Takeda has built a system to instill its corporate philosophy throughout the organization and manage risks based on its values.

Unless a corporate philosophy is embedded into specific organizational structures and processes, it remains an abstract slogan. Governance structures (Board oversight, various committees, code of conduct) are the primary mechanisms for translating high-level principles into daily operations and ensuring accountability, especially in a large global corporation.

Takeda’s emphasis on Board independence, global expertise⁷, and clear alignment with its corporate philosophy⁷ suggests an intentional effort to use governance not just for compliance, but as a "system" to guarantee that philosophy is applied consistently across the organization. Proactive adherence to the Corporate Governance Code⁷ demonstrates that its internal value system is valid even by external standards, reinforcing the message of "Integrity" (Takedaheadism).

In essence, Takeda views its corporate governance framework not as a mere compliance necessity, but as a critical "operational infrastructure" for embedding and maintaining its philosophy (Takedaheadism, PTRB) throughout its complex global operations. The structure and composition of the Board and internal controls are designed to ensure that strategic decisions and daily operations remain aligned with its declared Purpose, Vision, and Values.

Takedaheadism Creates Sustainable Corporate Value

Takeda’s philosophy-driven management aims to do more than just guide strategy and operations; it seeks to contribute to long-term corporate value creation. Its impact spans diverse aspects, including business performance, market evaluation, employee engagement, and brand value.

Implications for Business Performance and Market Evaluation

Looking at Takeda’s recent performance, revenue has been on an upward trend (totaling ¥4.2638 trillion in FY2023¹⁹) due to the effects of the Shire acquisition and the growth of mainstay products such as the ulcerative colitis treatment Entyvio²⁰. However, operating profit and net profit decreased significantly in FY2023 compared to the previous year, impacted by the amortization of intangible assets from the Shire acquisition²¹, increased investment in R&D and DX, and the impact of generic drugs¹⁹. In its company forecast for FY2024 (ending March 2025), Takeda expects revenue to increase by 7.7% to ¥4.59 trillion and operating profit to rise by 60.7% to ¥344 billion, but predicts an 18.1% decrease in net profit to ¥118 billion¹⁹.

Regarding market evaluation, analyst ratings are largely "Buy" or "Slightly Bullish," with target prices set above current levels, reflecting expectations for future potential²². Conversely, the Price-to-Book Ratio (PBR) has been trending below 1x²³. This suggests that the market may not be valuing Takeda’s asset value (particularly the massive goodwill and intangible assets recorded from the Shire acquisition) or future profitability at their book value.

Proving a direct causal link between corporate philosophy and short-term performance or stock price is difficult. It is not possible to conclude from the provided information alone the extent to which Takeda’s emphasis on "Patient First," "Trust," and "Reputation" leads to product loyalty, pricing power, or investor confidence. Rather, Takeda’s philosophy aims for "sustainable management and growth" and "long-term value creation"¹⁸, and it can be said that there are aspects that do not necessarily align with short-term fluctuations in financial indicators.

Philosophy-driven strategies—particularly those prioritizing stakeholders like patients and long-term reputation (PTRB)—often involve investments that may weigh on short-term profits (R&D, post-merger integration, sustainability activities). Takeda’s recent financials reflect the massive investment in Shire, integration costs, and the potential impact of patent expiries²¹, leading to lower reported profits despite revenue growth¹⁹.

Stock markets often react to short-term earnings and balance sheet metrics. A PBR of less than 1x²³ likely reflects market skepticism regarding the valuation of acquired assets (especially Shire’s intangibles) and concerns about short-term profitability and debt levels¹¹. On the other hand, optimistic analyst views²² may indicate confidence in the long-term strategic vision (such as the potential of the R&D pipeline²¹) despite short-term headwinds, which would align with Takeda’s own long-term value creation story.

A clear "tension" exists here between Takeda’s long-term, philosophy-driven value creation narrative (emphasizing Patient, Trust, and Reputation) and its current market evaluation (PBR < 1), which is likely influenced by the financial impact of the Shire acquisition and short-term profit pressures. While analysts seem to believe in the long-term potential, market indicators suggest that investors are still weighing the costs and risks of transformation against the promised future value from the philosophy-guided strategy. This highlights a challenge faced by many companies: aligning long-term Purpose with short-term financial expectations.

Fostering Employee Engagement and Organizational Culture

The "People" promise in Takeda’s corporate philosophy translates into specific initiatives aimed at improving employee engagement and fostering a diverse and inclusive organizational culture³.

The company emphasizes Diversity, Equity & Inclusion (DE&I)²⁴ and has received the highest "Gold" rating in Japan’s "PRIDE Index" for initiatives such as creating an LGBTQ+-friendly workplace²⁴. Furthermore, it has been certified as a "Global Top Employer®" by the Top Employers Institute® for seven consecutive years (as of January 2024)²⁵, indicating high marks for its efforts to realize ideal working styles for employees²⁵. High scores in categories such as "Ethics & Integrity" and "Purpose & Values" serve as evidence that the corporate philosophy is reflected in HR policies²⁵. These certifications are obtained not only globally but also individually in many countries and regions, including Japan²⁵ and the Philippines, where it has also received Great Place To Work® certification²⁶.

In Takeda’s recruitment activities, empathy with the corporate philosophy is emphasized. The desired candidate profile includes "people who empathize with Takedaheadism and can grow toward Takeda’s future for the sake of patients"²⁷, with empathy for the Purpose serving as a factor in attracting talent²⁸. The company also focuses on the acquisition and development of global and digital talent¹⁵.

Employee surveys also show high scores for items related to Purpose and Values, suggesting that the philosophy has permeated on a global scale and is rooted in the organization⁴. Employees have also shared that Takedaheadism was a value cherished within their families⁸ and that the patient-centric approach is deeply believed in⁵.

Takeda appears successful in transforming its philosophical commitment to "People" into a concrete employee experience, evidenced by consistent external evaluations (such as "Top Employer" certifications) and positive internal feedback⁴. This suggests that the philosophy is more than fine words; it actively shapes HR policies and working environments, creating tangible assets for talent acquisition, retention, and overall organizational health (such as improved employee engagement). This directly supports the "People" promise while indirectly reinforcing "Reputation" and "Business."

Enhancing Brand Value and Social Reputation

In the PTRB priorities, "Reputation" is positioned as a critical element following "Trust"³. Takeda engages in conscious brand-building activities to enhance this social reputation.

The corporate branding campaign launched on the company’s 240th anniversary, "Takeda: Serving the world. Innovatively. With integrity,"²⁹ is symbolic. This campaign aimed to communicate Takeda’s new form (an innovative, global biopharmaceutical company) following the Shire acquisition and its core values (Integrity) inherited since its founding, updating its image from that of a "long-established Japanese pharmaceutical company"³⁰.

The results of these efforts are beginning to appear in brand value assessments. Takeda recently ranked in the top 100 of Interbrand’s "Best Japan Brands" for the first time³¹. While this is a sign that Takeda’s brand is beginning to gain external recognition, the ranking itself (100th) may suggest that external awareness is still developing compared to the scale of internal transformation and the focus on branding.

Specific CSR (Corporate Social Responsibility) and ESG (Environmental, Social, and Governance) activities reinforce brand communication. Takeda engages in a wide range of social contribution activities, including a unique global CSR program where employees vote to determine support recipients³², healthcare support in developing countries (disease prevention, health worker training, improving access to medicine, etc.)³³, and recovery support for the Great East Japan Earthquake³⁴. These activities serve as concrete examples of practicing corporate philosophies like "Patient," "Trust," "Reputation," and "Planet," contributing to an improved brand image.

Furthermore, Takeda was an early adopter of the integrated report (which combines financial information with non-financial information such as ESG)³⁵, striving to communicate a comprehensive, philosophy-based value creation story to stakeholders like shareholders and investors¹⁸.

Takeda is engaged in conscious and strategic brand-building aimed at aligning external perception (brand image) with its deeply rooted internal philosophy (Takedaheadism) and transformed business model (global biopharmaceutical company). The "Takeda: Serving the world" campaign and supporting CSR/ESG activities are key tools in this effort. While early progress is visible, such as the debut in brand value rankings, establishing broad external recognition (high brand evaluation) that fully reflects the strong internal commitment to Takedaheadism will likely remain a key ongoing goal for enhancing "Reputation" and "Trust."

Conclusion

As analyzed in this article, Takeda Pharmaceutical Company’s corporate philosophy system—particularly Takedaheadism and the PTRB framework—is not a static set of mottos but a "strategic asset" that is actively managed and utilized. It plays a clear role in guiding daily decision-making⁴, directing large-scale strategic shifts like the Shire acquisition⁹, supporting global governance⁷, fostering a positive organizational culture valued by employees²⁵, and driving post-transformation brand image construction³².

However, its impact is not simple. Particularly as the financial burden and integration costs following the Shire acquisition weigh on short-term profitability, we observed the difficulty of constantly aligning a long-term, philosophy-driven value creation story with short-term financial indicators and market evaluations (such as PBR)¹⁹. Critical external views regarding the M&A strategy also exist¹¹. This reflects the universal challenge faced by many companies: how to balance "Purpose" (social reason for being) with "Profit" and engage in dialogue with the market.

Takeda’s case offers several strategic implications for corporate management, those in charge of organizational culture and branding, and students considering their future careers:

• Operationalizing Philosophy: The importance of translating philosophy into a clear framework like PTRB that can be "used" in daily decision-making.
• Leadership Commitment: The necessity for management, including the CEO, to consistently communicate the importance of the philosophy and embody it themselves⁵.
• Embedding in Governance: The need to deeply embed philosophy into governance structures and processes to ensure it is practiced throughout the organization rather than becoming a mere formality.
• Anchor During Transitions: How a shared philosophy can serve as an "anchor," providing stability and direction for an organization during periods of intense change, such as large-scale transformation or global integration.
• Concrete Proof Points: The indispensability of specific actions (Proof Points) that support the philosophy—such as CSR/ESG activities and superior employee experiences—to build a brand and reputation based on those ideals.
• Dialogue with the Market: The need for constructive and continuous dialogue between management based on long-term Purpose and a market that expects short-term financial results.

In conclusion, Takeda’s journey demonstrates that a deeply rooted corporate philosophy, if properly managed and adapted, can serve as a powerful differentiator and a compass for pursuing sustainable, long-term value creation and navigating complexity, even in the highly competitive global pharmaceutical industry. Takedaheadism will continue to be a vital foundation linking Takeda’s past and present and shaping its future.

出典

Footnotes

1. Company Motto/Principles 18: Takeda Pharmaceutical Company | Shunen Club, accessed April 13, 2025, http://shunen.jp/676/ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

2. What Going Digital Means for Takeda | EY Japan, accessed April 13, 2025, https://www.ey.com/ja_jp/insights/consulting/what-going-digital-means-for-takeda ↩ ↩² ↩³ ↩⁴

3. Corporate Philosophy | Takeda Pharmaceutical, accessed April 13, 2025, https://www.takeda.com/jp/about/our-company/corporate-philosophy/ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

4. Global-Standard "Purpose Management" Capturing the Present from the Future | Purpose ..., accessed April 13, 2025, https://www.240.takeda.com/governance/01/ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

5. Interview: José Manuel Caamaño - General Manager, Takeda Mexico - Pharma Boardroom, accessed April 13, 2025, https://pharmaboardroom.com/interviews/interview-jose-manuel-caamano-general-manager-takeda-mexico/ ↩ ↩² ↩³

6. Adapt to Different Cultures Like a Chameleon - Asahi Shimbun GLOBE+, accessed April 13, 2025, https://globe.asahi.com/article/12159173 ↩

7. Why is the Governance of Long-Established Takeda Pharmaceutical Excellent? The Truth ..., accessed April 13, 2025, https://forbesjapan.com/articles/detail/46401 ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

8. Takedaheadism Passed Down Through Generations | Takeda Pharmaceutical, accessed April 13, 2025, https://www.takeda.com/jp/our-impact/our-stories/aki/ ↩ ↩²

9. Regarding Takeda's Offer to Acquire Shire, accessed April 13, 2025, https://www.takeda.com/jp/newsroom/newsreleases/2018/20180508_7964/ ↩ ↩² ↩³

10. Takeda's M&A Strategy: Toward a Global Multinational Company - Prove Co., Ltd., accessed April 13, 2025, https://www.provej.jp/column/st/takeda-ma-medical/ ↩

11. Verification of Takeda's M&A Strategy Failure: 10 Trillion Yen and the Outflow of Human Resources! | Yujiro Hara | Book | Amazon, accessed April 13, 2025, https://www.amazon.co.jp/%E6%AD%A6%E7%94%B0%E8%96%AC%E5%93%81M-A%E6%88%A6%E7%95%A5-%E5%A4%B1%E6%95%97%E3%81%AE%E6%A4%9C%E8%A8%BC-%E2%80%9510%E5%85%86%E5%86%86%E3%81%A8%E4%BA%BA%E6%9D%90%E3%81%AE%E6%B5%81%E5%A4%B1-%E5%8E%9F%E9%9B%84%E6%AC%A1%E9%83%8E/dp/4865813519 ↩ ↩² ↩³ ↩⁴ ↩⁵

12. Takeda Pharmaceuticals | Global Website, accessed April 13, 2025, https://www.takeda.com/jp/ ↩

13. Takeda R&D and the Center for External Innovation - METI, accessed April 13, 2025, https://www.meti.go.jp/shingikai/economy/mukei_shisan/pdf/003_s03_00.pdf ↩ ↩²

14. Takeda's Serious Digital Talent Development: Seeing Data & Digital as Underpinning Philosophy Realization - HRzine, accessed April 13, 2025, https://hrzine.jp/article/detail/4171 ↩ ↩²

15. Takeda Partners with Accenture and AWS to Accelerate Digital Transformation, accessed April 13, 2025, https://newsroom.accenture.jp/jp/news/2020/release-20201014 ↩ ↩²

16. Takeda Pharmaceutical Company Limited - Sapporo Securities Exchange, accessed April 13, 2025, https://www.sse.or.jp/wp-content/uploads/2024/07/20240710_45020_ged.pdf ↩

17. Human Capital of Takeda Pharmaceutical [4502] - Kitaishihon, accessed April 13, 2025, https://kitaishihon.com/company/4502/human-capital ↩

18. fs2.magicalir.net, accessed April 13, 2025, https://fs2.magicalir.net/tdnet/2023/4502/20230706518696.pdf ↩ ↩² ↩³

19. Takeda Pharmaceutical (4502) Financial Results - Performance Trends - Kabutan, accessed April 13, 2025, https://kabutan.jp/stock/finance?code=4502 ↩ ↩² ↩³ ↩⁴ ↩⁵

20. Corporate Analysis of Takeda Pharmaceutical (for career change/employment) - note, accessed April 13, 2025, https://note.com/recruit_support/n/nb4e56182cc93 ↩

21. Analysis of Takeda Pharmaceutical's Growth Strategy, accessed April 13, 2025, https://yorozuipsc.com/uploads/1/3/2/5/132566344/953565c5f7c8bac02a1c.pdf ↩ ↩² ↩³

22. Takeda Pharmaceutical (4502): Analyst Forecast Stock Price / Pro Forecast [TPC] - Minkabu, accessed April 13, 2025, https://minkabu.jp/stock/4502/analyst_consensus ↩ ↩²

23. Takeda Pharmaceutical (4502): Theoretical Stock Price / Target Stock Price | Kabu Yoho Pro, accessed April 13, 2025, https://kabuyoho.jp/sp/reportTarget?bcode=4502 ↩ ↩²

24. Takeda - Takeda's DE&I, accessed April 13, 2025, https://www.takeda.com/jp/careers/dei/ ↩ ↩²

25. Takeda Certified as Global Top Employer for 6 Consecutive Years - Iyaku Tsushinsha, accessed April 13, 2025, https://iyakutsushinsha.com/2023/01/17/global-top-employer%E3%81%AB6%E5%B9%B4%E9%80%A3%E7%B6%9A%E3%81%A7%E8%AA%8D%E5%AE%9A%E3%80%80%E6%AD%A6%E7%94%B0%E8%96%AC%E5%93%81/ ↩ ↩² ↩³ ↩⁴ ↩⁵

26. A Great Place To Work Certified™ for the Third Consecutive Year | Takeda Philippines, accessed April 13, 2025, https://www.takeda.com/en-ph/press-releases/2024/philippines-earns-great-place-to-work-certification/ ↩

27. [Corporate Research] Thorough Explanation of Takeda Pharmaceutical's Employment Difficulty, Recruited Universities, and Selection Measures, accessed April 13, 2025, https://jo-katsu.com/campus/9295/ ↩

28. What a Company Should Have for Longevity is "Purpose" - Takeda and PwC's Perspective - Forbes JAPAN, accessed April 13, 2025, https://forbesjapan.com/articles/detail/48304 ↩

29. Stories of Takeda Pharmaceutical Company Limited - PR TIMES, accessed April 13, 2025, https://prtimes.jp/main/html/searchrlp/company_id/90178?tab=story ↩

30. Takeda's 240th Anniversary: Bringing Consciousness Change Internally and Externally Through Inclusive Communication, accessed April 13, 2025, https://mag.sendenkaigi.com/kouhou/202206/longlife-anniversary/023906.php ↩

31. "Brand Value Ranking of Japanese Companies": Takeda Pharmaceutical Ranks for the First Time, accessed April 13, 2025, https://www.advertimes.com/20240222/article449755/ ↩

32. Behind the Scenes: Latest in "Serving the world, Takeda" Commercial Series Set in Osaka Plant - PR TIMES, accessed April 13, 2025, https://prtimes.jp/story/detail/bKonY4UWOWb ↩ ↩²

33. Takeda Pharmaceutical Company Limited - Registered Organization Details - JICA PARTNER, accessed April 13, 2025, https://partner.jica.go.jp/Org/Detail/1667 ↩

34. Why Support Recipients for CSR Programs are Decided by Votes from 50,000 Global Employees - PR TIMES, accessed April 13, 2025, https://prtimes.jp/story/detail/bykmZWS2D2x ↩

35. What is the Process of Creating an Integrated Report? | Koho Kaigi Digital Edition - Sendenkaigi, accessed April 13, 2025, https://mag.sendenkaigi.com/kouhou/201407/integrated-reporting/002642.php ↩